PTGX – Protagonist Therapeutics Inc
PTGX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.59
Margin Of Safety %
-32
Put/Call OI Ratio
0.38
EPS Next Q Diff
0.07
EPS Last/This Y
6.52
EPS This/Next Y
-4.66
Price
145.99
Target Price
152.14
Analyst Recom
1.21
Performance Q
47.57
Upside
-90.7%
Beta
1.79
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | PTGX | 129.79 | 0.46 | 1.21 | 7911 |
| 2026-07-14 | PTGX | 131.39 | 0.47 | 0.88 | 7954 |
| 2026-07-15 | PTGX | 136.2 | 0.47 | 1.53 | 7989 |
| 2026-07-16 | PTGX | 132.18 | 0.47 | 0.05 | 8008 |
| 2026-07-17 | PTGX | 141.03 | 0.47 | 0.06 | 8003 |
| 2026-07-20 | PTGX | 133.83 | 0.38 | 2.21 | 6126 |
| 2026-07-21 | PTGX | 138.19 | 0.39 | 0.00 | 6150 |
| 2026-07-22 | PTGX | 135.35 | 0.39 | 0.02 | 6147 |
| 2026-07-23 | PTGX | 135.26 | 0.34 | 0.00 | 6816 |
| 2026-07-24 | PTGX | 136.21 | 0.31 | 0.67 | 7463 |
| 2026-07-27 | PTGX | 135.63 | 0.31 | 0.00 | 7489 |
| 2026-07-28 | PTGX | 136.78 | 0.31 | 0.08 | 7590 |
| 2026-07-29 | PTGX | 132.78 | 0.31 | 0.33 | 7600 |
| 2026-07-30 | PTGX | 138.61 | 0.31 | 0.06 | 7615 |
| 2026-07-31 | PTGX | 136.85 | 0.31 | 0.15 | 7592 |
| 2026-08-03 | PTGX | 132.4 | 0.31 | 3.83 | 7612 |
| 2026-08-04 | PTGX | 136.63 | 0.31 | 0.83 | 7645 |
| 2026-08-05 | PTGX | 137.52 | 0.32 | 47.00 | 7672 |
| 2026-08-07 | PTGX | 146 | 0.38 | 1.59 | 8229 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | PTGX | 129.89 | 422.5 | - | 4.19 |
| 2026-07-14 | PTGX | 131.41 | 422.5 | - | 4.19 |
| 2026-07-15 | PTGX | 135.56 | 422.5 | - | 4.19 |
| 2026-07-16 | PTGX | 132.04 | 422.5 | - | 4.19 |
| 2026-07-17 | PTGX | 140.91 | 422.5 | - | 4.19 |
| 2026-07-20 | PTGX | 134.02 | 422.4 | - | 4.19 |
| 2026-07-21 | PTGX | 138.22 | 424.4 | - | 4.21 |
| 2026-07-22 | PTGX | 135.55 | 424.4 | - | 4.21 |
| 2026-07-23 | PTGX | 135.36 | 450.7 | - | 4.47 |
| 2026-07-24 | PTGX | 136.26 | 450.7 | - | 4.47 |
| 2026-07-27 | PTGX | 135.63 | 450.7 | - | 4.47 |
| 2026-07-28 | PTGX | 136.72 | 450.7 | - | 4.47 |
| 2026-07-29 | PTGX | 132.78 | 450.7 | - | 4.47 |
| 2026-07-30 | PTGX | 138.73 | 450.7 | - | 4.47 |
| 2026-07-31 | PTGX | 136.82 | 450.7 | - | 4.47 |
| 2026-08-03 | PTGX | 132.24 | 450.7 | - | 4.47 |
| 2026-08-04 | PTGX | 132.24 | 450.7 | - | 4.47 |
| 2026-08-05 | PTGX | 137.54 | 450.7 | - | 4.47 |
| 2026-08-06 | PTGX | 146.32 | 450.7 | - | 4.47 |
| 2026-08-07 | PTGX | 145.99 | 450.7 | - | 4.47 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | PTGX | -12.99 | 12.83 | 12.60 |
| 2026-07-14 | PTGX | -12.99 | 12.83 | 12.60 |
| 2026-07-15 | PTGX | -12.99 | 12.83 | 12.60 |
| 2026-07-16 | PTGX | -12.99 | 12.83 | 12.60 |
| 2026-07-17 | PTGX | -12.99 | 12.83 | 12.60 |
| 2026-07-20 | PTGX | -12.99 | 12.90 | 12.60 |
| 2026-07-21 | PTGX | -12.99 | 12.90 | 12.60 |
| 2026-07-22 | PTGX | -11.76 | 12.90 | 12.60 |
| 2026-07-23 | PTGX | -11.76 | 12.90 | 12.60 |
| 2026-07-24 | PTGX | -11.76 | 12.90 | 12.60 |
| 2026-07-27 | PTGX | -11.76 | 12.90 | 13.59 |
| 2026-07-28 | PTGX | -8.87 | 12.90 | 13.59 |
| 2026-07-29 | PTGX | -8.87 | 12.90 | 13.59 |
| 2026-07-30 | PTGX | -8.87 | 12.90 | 13.59 |
| 2026-07-31 | PTGX | -8.87 | 12.90 | 13.59 |
| 2026-08-03 | PTGX | -8.87 | 13.79 | 13.59 |
| 2026-08-04 | PTGX | -8.87 | 13.79 | 13.59 |
| 2026-08-05 | PTGX | -8.87 | 13.79 | 13.59 |
| 2026-08-06 | PTGX | -8.87 | 13.79 | 13.59 |
| 2026-08-07 | PTGX | -8.36 | 13.79 | 13.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.29
Avg. EPS Est. Current Quarter
1.93
Avg. EPS Est. Next Quarter
2.36
Insider Transactions
-8.36
Institutional Transactions
13.79
Beta
1.79
Average Sales Estimate Current Quarter
211
Average Sales Estimate Next Quarter
214
Fair Value
99.55
Quality Score
60
Growth Score
37
Sentiment Score
86
Actual DrawDown %
1.4
Max Drawdown 5-Year %
-85.8
Target Price
152.14
P/E
140.65
Forward P/E
PEG
P/S
33.47
P/B
11.21
P/Free Cash Flow
72.29
EPS
1.04
Average EPS Est. Cur. Y
4.47
EPS Next Y. (Est.)
-0.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
29.4
Relative Volume
0.46
Return on Equity vs Sector %
-17.5
Return on Equity vs Industry %
-1.4
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.29
EBIT Estimation
◆
PTGX
Healthcare
$145.87
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
64.8
Range 1M
91%
Sup Dist
3.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
319%
EPS NY
-111.1%
52W%
97.9%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-17.4% upside
Upside
-17.4%
Quality
60
MoS
-32%
PTGX — P/E HistoricalBiotechnology
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 141
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX
Latest News
—
Caricamento notizie per PTGX…
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading